Original articleTreatment of Refractory Uveitis with Adalimumab: A Prospective Multicenter Study of 131 Patients
Section snippets
Design and Enrollment Criteria
A prospective open-label noncomparative and multicenter study was conducted in the outpatient clinics of the Services of Ophthalmology or Uveitis Units of 12 centers throughout Spain and 2 centers in Latin America (Mexico, DF, Mexico, and Caracas, Venezuela) in daily practice conditions. The objective of the study was to evaluate adalimumab for treating patients with bilateral or unilateral, chronic, noninfectious, refractory uveitis. Uveitis was defined as refractory when patients were
Discussion
This is a prospective adalimumab treatment study in a large clinical series of 131 patients, and this anti–TNF-α agent seems to be an effective and well-tolerated treatment for patients with chronic, therapy-resistant, noninfectious uveitis. The effectiveness of adalimumab was demonstrated by a statistically significant decrease of anterior chamber and vitreous cavity inflammation, overall gain in visual acuity, reduction of macular thickness, and decrease of the immunosuppression load. In
Acknowledgment
The authors thank Marta Pulido, MD, for writing assistance and extensive editing of the scientific content.
References (32)
- et al.
Incidence and prevalence of uveitis in Northern California: the Northern California Epidemiology of Uveitis Study
Ophthalmology
(2004) - et al.
Standardization of vitreal inflammatory activity in intermediate and posterior uveitis
Ophthalmology
(1985) - et al.
Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study
Ophthalmology
(2006) - et al.
Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series
Ophthalmology
(2005) - et al.
Adalimumab therapy for childhood uveitis
J Pediatr
(2006) - et al.
Epidemiology of uveitis
Curr Opin Ophthalmol
(1995) - et al.
Uveitis: a global perspective
Ocul Immunol Inflamm
(2002) - et al.
The possible impact of uveitis in blindness: a literature survey
Br J Ophthalmol
(1996) - et al.
Uveitis and systemic disease
Br J Ophthalmol
(1992) - et al.
Immunopathology and altered immunity in posterior uveitis in man: a review
Curr Eye Res
(1992)
The role of T cells in autoimmune uveitis
Ocul Immunol Inflamm
New developments in corticosteroid therapy for uveitis
Ophthalmologica
Anti-TNF-alpha therapy for uveitis: Behçet and beyond
Eye (Lond)
Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis
Ophthalmic Res
Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27
Curr Med Res Opin
Use of tumor necrosis factor inhibitors in uveitis
Curr Opin Rheumatol
Cited by (191)
Biologic therapies for psoriasis and eyes
2023, Clinics in DermatologyAtteintes oculaires des maladies systémiques: Ocular involvement in systemic diseases
2022, Revue de Medecine InterneLong-Term Follow-up of Patients With Uveitis Treated With Adalimumab: Response Rates and Reasons for Discontinuation of Therapy
2022, American Journal of OphthalmologyLower Relapses Rate With Infliximab Versus Adalimumab in Sight-Threatening Uveitis: A Multicenter Study of 330 Patients
2022, American Journal of OphthalmologyCitation Excerpt :The estimated relapse rate at 6 months after introduction of biological agents was 13%. The rate of relapse found in our cohort is consistent with the scarce literature found on this subject.4,5 A relapse rate of 23.7%, and a median time to first flare of 5.4 years were reported by al Janabi et al in their retrospective study of 82 patients treated with IFX and ADA for refractory NIU.17
Manuscript no. 2011-1035.
Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article.